Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's Q3 Revenues Grow 24 Percent, Loss Rises

NEW YORK (GenomeWeb News) — Third Wave Technologies today said third-quarter revenues grew 24 percent as R&D spending rose 68 percent and its net loss widened 25 percent. 
Total receipts for the three months ended Sept. 30 increased to $8.2 million from $6.6 million year over year.
Revenue from clinical products rose 25 percent to $6.7 million, while receipts from research products increased 19 percent to $1.4 million.
The firm’s R&D expenses rose to $5.8 million from $3.5 million the previous year.
Third Wave’s net loss for the period swelled to $6.4 million from $5.2 million year over year, due in part to $1.8 million in litigation charges during the quarter.
The firm is locked in an ongoing patent and antitrust dispute with Digene, which recently was acquired by Qiagen.
Third Wave had around $43.6 million in cash, cash equivalents, and short-term investments as of Sept. 30.
The company also reaffirmed its previously announced guidance of 2007 clinical molecular diagnostics revenue of $26 million to $28 million and total revenue of $31 million to $33 million.
"We believe Third Wave is well positioned to create a sustainable competitive advantage through unique HPV products and an automated instrument offering, and through leadership in the rapidly-growing hospital laboratory market,” Third Wave President and CEO Kevin Conroy said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more